AIM
AMEXAIM ImmunoTech Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks62-58%
2026-04-192026-10-11
Mix2590d
- Other11(44%)
- SEC Filings9(36%)
- Insider4(16%)
- Market1(4%)
Latest news
25 items- PRAIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense PotentialOCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted recent media coverage of the antiviral potential of Ampligen® (rintatolimod), the Company’s investigational dsRNA and highly selective TLR3 agonist immunomodulator. Healthcare Business Today: AIM ImmunoTech CEO Tom Equels on Why Broad-Spectrum Antiviral Preparedness Cannot Wait for the Next OutbreakMediTech Today: What AIM ImmunoTech’s New Long COVID Patent Protection Says About the Future of Post-Viral Therapeutics The recent coverage reflects growing attention around Ampligen’s potential broad-spectrum antiviral and biodefense preparedness applications, including the
- PRAIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline DataOCALA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted recent media coverage focused on the Company’s development strategy for Ampligen® (rintatolimod) in metastatic pancreatic cancer, including the scientific rationale for targeting immune resistance and the continued advancement of the Phase 2 DURIPANC clinical trial ("DURIPANC"). Recent coverage includes: Med World News: AIM ImmunoTech’s Ampligen Program Targets One of Pancreatic Cancer’s Hardest BarriersPharma Tech News: Inside AIM ImmunoTech’s Ampligen Strategy for Targeting Immune Resistance in Pancreatic Cancer Pancreatic cancer remains one of the most difficult ca
- SECSEC Form DEF 14A filed by AIM ImmunoTech Inc.DEF 14A - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner VideoCompany highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones Access it here OCALA, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the release of a new installment of its CEO Corner series featuring Chief Executive Officer Thomas K. Equels discussing how Ampligen® (rintatolimod) could fit into the evolving treatment landscape for pancreatic cancer. In the CEO Corner, Equels discusses recent advances in pancreatic cancer treatment and why AIM believes Ampligen’s distinct immune-modulating approach warrants continued investigation. Rather than
- PRAIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ DaraxonrasibCompany CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months in a selected pancreatic patient population versus 12.5 months in historical controls OCALA, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today issued a letter to stockholders from Chief Executive Officer Thomas Equels addressing the recent U.S. Food and Drug Administration (the "FDA") approval of daraxonrasib and outlining the Company’s view of Ampligen’s differentiated mechanism, clinical profile and potential role in th
- INSIDERCEO & President Equels Thomas K bought $4,992 worth of shares (24,000 units at $0.21), increasing direct ownership by 23% to 126,822 units (SEC Form 4)4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
- INSIDERCEO & President Equels Thomas K bought $2,310 worth of shares (11,000 units at $0.21), increasing direct ownership by 12% to 102,822 units (SEC Form 4)4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
- INSIDERCEO & President Equels Thomas K bought $4,862 worth of shares (22,000 units at $0.22), increasing direct ownership by 32% to 91,822 units (SEC Form 4)4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
- INSIDERCEO & President Equels Thomas K bought $1,292 worth of shares (5,900 units at $0.22), increasing direct ownership by 9% to 69,822 units (SEC Form 4)4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner VideoCompany continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen’s potential to reshape the tumor microenvironment and enhance checkpoint inhibition Access it here OCALA, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the release of a new installment of its CEO Corner series featuring Chief Executive Officer Thomas K. Equels discussing the Company’s scientific strategy and continued advancement of Ampligen® (rintatolimod) in pancreatic cancer. In the CEO Corner, Equels discusses the significant challenges associated with pancreatic cancer, including its highly immunosuppressive – or "c
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom Latest milestone further strengthens AIM’s expanding global Ampligen patent estate across multiple therapeutic opportunities Follows newly issued U.S. patent covering Ampligen in combination with pembrolizumab for the treatment of cancer OCALA, Fla., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced three forms of patent protection in Europe and the United Kingdom covering the use of the Company’s drug Ampligen in the treatment of Long COVID, also known as post-viral long-term symptoms followi
- PRAIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the United States Patent and Trademark Office has granted a patent covering the use of the Company's drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer. This newly issued U.S. patent expires December 20, 2039. Ampligen is a wide-spectrum Toll-like receptor 3 (TLR3) agonist, among other biological effects, and has been investigated for the treatment of various cancers, among other conditions. The Company has been issued multiple patents, and has filed multiple additional patent applications, directed to the use of
- PRAIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand ConferenceVideo webcast now available here OCALA, Fla., Aug. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, AIM Chief Executive Officer Thomas Equels presented the Company's investment thesis, highlighting why he believes now is a pivotal time for AIM. The presentation discusses the Company's progress advancing Ampligen® through the Phase 2 DURIPANC clinical trial in metastatic pancreatic cancer, including successful completion of enrollment ahead of schedule, Ampligen dosing of the final patient and the anticipated transition into primary endpoint
- NEWSJTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming catalysts and the opportunities management believes investors should be watching todayAccess on demand conference here FRENCHTOWN, NJ / ACCESS Newswire / August 27, 2026 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the release of its Virtual Investor "Why Now" On-Demand Conference, featuring a fast-paced series of 60-second presentations from the CEOs of nine publicly traded companies.The premise is simple: Why sho
- PRAIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ ArticleArticle by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge Highlights Company’s investigational drug Ampligen® (rintatolimod) and its potential application as a broad-spectrum prophylactic or early-onset antiviral countermeasure in Ebola and its variants Access the article here OCALA, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the publication of an article authored by AIM Chief Executive Officer Thomas K. Equels in "Breaking Defense" titled, "Biodefense is force protection: Ready today, prepared for tomorrow." The article, which includes
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form 8-K filed by AIM ImmunoTech Inc.8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic CancerCompleted Enrollment and Ampligen Dosing in Metastatic Pancreatic Cancer Phase 2 Trial, Positioning Company for Key Clinical Milestones Through Early 2027 Pancreatic Cancer Remains Strategic Priority as AIM Advances Toward Planned Phase 3 Development While Seeking Select Government-Funded Infectious Disease Initiatives in Ebola OCALA, Fla., Aug. 10, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported financial results for the second quarter ended June 30, 2026, and provided a business update highlighting continued operational execution across its lead pancreatic cancer program. "AIM continues to execute a clear and disciplined strategy centere
- SECSEC Form 10-Q filed by AIM ImmunoTech Inc.10-Q - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Shareholder Director Nominations, Financial Statements and Exhibits8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection PointOCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod) under the study protocol, reaching this milestone ahead of schedule in the Phase 2 DURIPANC clinical trial evaluating Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of metastatic pancreatic cancer. Following planned data collection, DURIPANC Primary Endpoint analysis is anticipated to begin in December 2026 and topline results are anticipated in Q1 2027. DURIPANC’s primary endpoint is Clinical Benefit Rate ("CBR"), defi
AIM FAQ
5 questionsWhat does AIM ImmunoTech Inc. do?
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides...Where does AIM stock trade?
AIM ImmunoTech Inc. (AIM) is listed on AMEX.What sector and industry is AIM in?
AIM ImmunoTech Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to AIM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare AIM side-by-side with any of them on Quantisnow.How can I track AIM on Quantisnow?
Quantisnow aggregates AIM ImmunoTech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AIM to receive live email and push alerts on every new disclosure.